Clinical trial · no report yet · Phase 2
NCT04564703
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
- NCT04564703 ↗
- Active not recruiting
- Stichting European Myeloma Network
- 20 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| X threads | 6 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide
- Arms
- cohort 1 · Experimental
- cohort 2 · Experimental
- cohort 3 · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Efficacy: rate of improvement in response with iberdomide maintenance after autologous stem cell transplantation (ASCT)
- Rate of dose reductions/discontinuations with iberdomide maintenance after ASCT
- Sponsor
- Stichting European Myeloma Network with Healt Data Specialists - HeaDS (CRO), EMN Research Italy Impresa Sociale Srl
- Start
- Feb 22, 2021
- Primary completion
- Jul 27, 2023
- Results posted
- No
- Registry record
- NCT04564703 · updated Jul 16, 2026